Skip to main content
Equibles
MLYS logo

MLYS · Mineralys Therapeutics, Inc.

Track MLYS — free

Use MLYS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MLYS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$28.20 -1.10 (-3.75%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$2.59B
Shares
88.41M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$28.20 Open$29.65 Day$28.17–29.95 52W close$22.50–47.33 Avg vol 30d972K Short int9.3M · 10.6% float · 11.4d Short vol17% Last earningsAug 11, 2026 DataFeb 2023–Sep 2026 Filing10-Q · Aug 11

Up next

Next earnings call
Nov 13, 2026 Est · unconfirmed · in 9 wks
Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$349.58M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$138.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.5%
Year over year · more shares
Price change (1Y)
-24.0%
Trailing year
Short interest
10.6%
Latest settlement · 11.4 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg −4%
below
Price vs 50-day avg +4%
above
RSI (14) 53
neutral
MACD trend Positive
52-week position 23%
mid-range
Momentum
relative strength
Strong
1-month return +8%
trailing
6-month return +17%
trailing
YTD return −22%
this year
Relative strength −1%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $27 › 200d $29 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.56% of float · ▼ -3.3% MoM · 11.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
227 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 60%
annualized · 1-yr
Max drawdown −52%
past year
ATR 5.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−4% Neutral
Price vs 50-day avg
+4% Bullish
RSI (14)
53 Neutral
MACD trend
Positive Bullish
52-week position
23% Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $27 › 200d $29 — 200d above 50d
Institutional flow Accumulating
+4% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.56% of float · ▼ -3.3% MoM · 11.4 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
227 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $23 Now $28 · 23% Range high $47
vs 200-day avg -4% vs 50-day avg +4%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MLYS
Mineralys Therapeutics, Inc.
this stock
$2.59B -22.3% — — 10.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
227
% held
115.8%
Net QoQ
+4.7M sh
Top holder
Catalys Pacific, LLC
Held Float
View
Held by Funds
Fund positions
238
View
Short & Settlement
Short Interest Falling
Shares short
9.3M
Days to cover
11.4d
Change
-313.6K sh
View
Short Volume
Short vol %
17%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
5.6K
Value
$149.0K
As of
Aug 6, 2026
View
Off-Exchange
Off-exchange %
36.1%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-154.7M
EPS diluted
$-2.29
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Sep 9, 2026
This year
15
View
Proposed Sales
Value
$67.0K
Shares
2.2K
Filed
Sep 9, 2026
View
Exempt Offerings
Offering
$118.0M
Filed
Jun 13, 2022
View
Earnings & Events
Earnings Calls
Last call
Sep 9, 2026
View

Performance

5D 20D 120D MTD YTD
MLYS -0.3% +8.1% +17.2% +9.9% -22.3%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +0.9% +9.8% -0.7% +10.2% -34.4%
Key facts CIK 1933414 CUSIP 603170101 13F (30d) 134 filings 133 filers Visit website Investor relations